



Marinus Pharmaceuticals
Investor Relations Department
170 N. Radnor Chester Road,
Suite 250
Radnor, PA 19087-5279
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: MRNS

| | |
|---------------|----------------------------|
| Last Trade: | 4.92 |
| Trade Time: | 4:00 PM ET Oct 18, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 0.82 - 8.22 |
| Volume | N/A |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 21, 2017*
[Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference](#)
- Sep 19, 2017*
[Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares](#)
- Sep 15, 2017*
[Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock](#)
- Sep 14, 2017*
[Marinus Pharmaceuticals Announces Public Offering of Common Stock](#)
- Sep 11, 2017*
[Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone](#)

Financials & Filings [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 13, 2017*
[Annual Report \(10-K\)](#)
- Mar 16, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 1, 2017*
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*
[Quarterly Report \(10-Q\)](#)